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Topical application of NSAIDs is an alternative route to systemic administration when a local anti-
inﬂammatory effect of the underlying tissue is a treatment option. The aim of the present microdialysis
study was to assess and compare plasma and tissue levels of diclofenac when topically applied with or
without iontophoresis in healthy adults. Fourteen healthy adults (2679.4 years) were randomized to
diclofenac applied by iontophoresis, or by a gel, in a crossover design. Diclofenac concentrations were
measured in plasma and in microdialysis perfusates from the underlying tissues. Iontophoretic
application resulted in the highest plasma concentration of 3.470.5 ng/ml (SEM given) compared to
0.4 ng/ml (at the detection limit) with gel, whereas no differences were observed between tissue
concentrations for the two application methods, both being very low, below or around the detection
limit. Iontophoresis caused skin reactions in 25% of the participants. Iontophoresis of diclofenac as
compared to traditional topical application was not superior in order to increase the NSAID
concentration locally and appears to have a higher frequency of skin reactions.
& 2011 Published by Elsevier B.V.1. Introduction
Topical or systemic applications of NSAIDs are frequently used
in management of musculoskeletal pain [30,13,7].
Oral intake of NSAIDs over an extended period of time can
cause ulcers, cardio-vascular events, and nephrotoxicity [12], and
hence long-term oral administration of NSAIDs for management
of e.g. osteoarthritis is not recommended [31]. Topical adminis-
tration of some NSAIDs (e.g. ibuprofen) is shown to give drug
concentrations in subcutaneous layers and underlying muscle
comparable to the orally administered drug [27]. Topical applica-
tion penetrates the skin slowly [30] and hence the onset of effect
is slower and may vary according to the pharmacokinetics of the
particular molecule to a higher degree than after systemic
administration [22,10].
Acute pain after acute traumatic injury responds to topical
application of diclofenac [23], but the efﬁcacy is dependent on
skin area covered, and type of application [13,1,16]. It is not
always clear how much and how fast the NSAID penetrates into
the tissue [30,10] since the absorption kinetics depends on theElsevier B.V.
þ45 38164159.
. Bartels),actual formulation [10]. Degree of skin dryness and differences in
thickness of the skin layers will also affect the penetration
[20,11]. To speed up transport, and thereby increase the NSAID
available in the tissue, the charged NSAID molecule may be driven
iontophoretically into the tissue [9,25,4,15,5,6,3], a method also
used for analgetics [26].
The aims of this study were to test (1) if diclofenac applied
together with iontophoresis leads to a faster transdermal trans-
port than standard topical application, (2) if drug concentration in
the subcutaneous layer and plasma differed between the two
application paradigms, and ﬁnally (3) compare the adverse effect
proﬁles.2. Methods
2.1. Subjects and treatments
Sixteen healthy subjects (5 men and 9 women, mean age
26.679.4 years, mean BMI 22.2 kg/m272.1 kg/m2) participated
in the study. All participants were Caucasians.
The study was carried out as a pilot trial for GlaxoSmithKline
Consumer Healthcare (GSKCH) according to protocol A2410337.
GSKCH participated in the writing of the protocol, but had no
further connection to or possibility of inﬂuencing the study.
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nancy, or being female and not using one of following birth
control methods: intra-uterine device or hormonal contracep-
tives, or being breast-feeding, hepatitis, renal insufﬁciency, con-
gestive heart failure, history of gastro-intestinal bleeding,
presence of any skin disorder, drug abuse (tested at enrolment),
or measurable alcohol breath.
Intake of any NSAIDs, topically or orally, during the whole
study period was furthermore prohibited, and the participants
had to abstain from exercise for at least three hours prior to
participating in the experiment.
The subjects were, following enrolment and screening, given a
physical examination by a clinician with recording of found
abnormalities prior to randomisation. The randomisation was
carried out by The Biostatics and Data Management Department,
GlaxoSmithKline Consumer Healthcare, Weybridge, UK, using a
computer programme and applying a Latin-square design. The
study was an open-label, two-period, crossover, active-compara-
tor design, where each participant would be exposed to both
treatment methods in the order they were randomised into,
receiving either 2.00 ml diclofenac potassium (2%) solution deliv-
ered via a iontophoretic patch with an area of 13 cm2, equivalent
to an amount of 35.44 mg diclofenac base, or to receive 4.00 g
Voltarol Emulgel Ps 1.16% diclofenac diethylammonium gel on a
skin area of 13 cm2, the amount of active substance being
equivalent to 37.22 mg diclofenac base. The dose 4.00 g of this
Voltarol Emulgel P is the maximum single dose recommended for
the marketed product. For iontophoresis a voltage of 4 V was
applied with a current density of 0.3–0.5 mA/cm2. The patch
was speciﬁcally produced for the study by GlaxoSmithKline,
Weybridge, UK, as a single-use iontophoretic patch, batch number
34905A-500 and 08706A-500, and quality assured for research
and development purposes prior to use. The two methods were
applied with a wash-out period of minimum four days, and the
two methods were applied on different shoulders and on the skin
over the trapezius muscle. The application of either patch or
Emulgel P was four hours, where after remaining gel or the patch
was removed. If the drug penetrates the skin, four hours is plenty
diffusion time to reach the underlying tissue [28,2].
2.2. Microdialysis system and assessment of penetration through
skin
Penetration of diclofenac was determined with microdialysis.
The system was prior to this study validated by GlaxoSmithKline,
Weybridge, UK. Custom-made microdialysis catheters composed
of a single plasmaphoresis hollow ﬁbre (0.3 mm in diameter,
molecular mass cut-off 100 kDa) from CMA Microdialysis (North
Chelmsford, MA 01863, USA) were used. A suture thread (Johnson
& Johnson, Brussels, Belgium) was glued to the membrane to
improve the mechanical stability of the catheter. Each catheter
was glued to a gas-tight nylon inlet and outlet tube (Portex
Autoclavable Nylon Tubing, Portex Limited, Smiths Industries,
Kent, England) and came in a sterile packing. Prior to use syringes
were sterilised with ethylene oxide.
Before inserting the microdialysis catheters, the skin and
subcutaneous tissues where the catheters entered were anaes-
thetised with a local injection of Xylocaine (20 mg/ml) without
adrenalin. Care was taken not to anaesthetise the underlying
fascia and muscle.
Determination of the location as well as the insertion of the
microdialysis tubes were carried out with ultrasound guidance
(General Electric, Logiq9TM, General Electric, Milwaukee, I1, USA),
using the M12L transducer to give a precise location of the
microdialysis tube. One tube was located in the centre of the
subcutaneous layer of the skin to follow the direct penetrationover the skin barrier. Another tube was located in a position
which was at one cm depth into the trapezius muscle to follow
penetration of drug into the tissue it was aimed for. Both tubes
were directly underneath the iontophoretic patch or the skin area
covered with gel. The exit sites were covered with a sterile plaster
(Tegaderm, 3 M, St. Paul, MN, USA) to prevent any direct penetra-
tion of diclofenac. Extracellular ﬂuid was collected from both
positions. The microdialysis catheters were perfused via a high-
precision syringe pump (CMA 100; Carnegie Medicine, Solna,
Sweden) at a rate of 2 ml min1 with a perfusate (Intralipid
20%s, Fresenius Kabi, Uppsala, Sweden) containing puriﬁed egg
phospholipids of the type used in parenteral nutrition. Sampling
times were half an hour prior to application of diclofenac, and
then at times 0 and every half hour thereafter, up to four hours
from time 0. The dialysates were frozen at 80 1C and stored
until end of the sample collection.
Blood tests were taken at time 0 and after 1, 2, and 4 h into
heparinised tubes, spun down, and plasma was stored at 80 1C
until end of the sample collection.
The plasma and dialysate samples were sent frozen to Medeval
Ltd., Manchester, UK, for measurements. Concentration of diclo-
fenac in the dialysates and the plasma samples was measured
by Medeval Ltd. with a validated liquid chromatography–Mass
Spectroscopy (LCMS-MS) method.
As efﬁcacy of a method of drug application, time for reaching
the muscle (dialysate) and/or total concentration reaching the
muscle was used. As a secondary measure, skin and plasma
concentrations of the drug were considered. Efﬁcacy of penetra-
tion into the sampling compartment was expressed by AUC(0-t),
Cmax and Tmax, i.e. the area under the concentration versus time
curve, the maximal concentration, and the time elapsed until the
maximal concentration was reached, in subcutaneous tissue,
muscle, and plasma. In these calculations it was assumed that
concentration equilibrium between the perfusion medium in the
microdialysis tube and its surrounding tissue is instantaneous,
which is the case with a fair approximation.
2.3. Ethics and safety
The study was approved by The Copenhagen and Frederiksberg
Municipality Ethics Committee (KF 02-286972) and The Danish
Medicine Agency, registered in the EUDRACT Database (EUDRACT
no. 2005-002791-15), and was carried out in accordance with the
guidelines given in the Helsinki Declaration of 1975, as revised in
1983. All participants gave their informed consent.
Tolerance and safety of the treatments applied in the study
was determined by a clinician assessing withdrawal and other
adverse events.
2.4. Possible bias
The study was carried out as a pilot trial for GlaxoSmithKline
Consumer Healthcare (GSKCH) according to protocol A2410337.
GSKCH participated in the writing of the protocol, but had no
possibility of inﬂuencing the data.
2.5. Data handling and statistics
Plasma concentration pharmacokinetic parameters, total
drug transport during the study period, and maximal drug
concentration achieved were log-transformed and analysed using
a linear mixed-effects analysis of variance (ANOVA) with factors
for subject (as a random effect), period, and treatment. The
residual mean square from the ANOVA was used to construct
conﬁdence intervals for the difference between treatments and
then expressed as a ratio.
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Wilcoxon’s rank sum test for a 22 crossover design, taking
sequence into account. Median difference in Tmax was calculated
using the Hodges–Lehmann one sample method. Subjects with
data from one period only were excluded from the Tmax analysis.3. Results
3.1. Pharmacokinetics
Both muscular and subcutaneous concentrations of diclofenac
were negligible in the majority of subjects, with 80% showing
values below the sensitivity limit (0.5 ng/ml), data not shown.
Iontophoretic application caused a maximal plasma concentration
of 3.470.5 ng/ml (7SEM) with a plateau from 2 h application, while
gel alone showed a similar pattern but only lead to a maximal
concentration of 0.4 ng/ml70.05 ng/ml (7SEM) which is below the
limit for analysis sensitivity (Fig. 1, Table 1).
Maximal concentration and total diclofenac delivered to
plasma was signiﬁcantly higher for the iontophoretically applied
drug than the standard gel application. There was no difference in
time for reaching maximal concentration with the two methods,
and with the clear plateau in both cases, a steady state appears to
have been reached in both (Fig. 1).
3.2. Safety
One subject in the iontophoresis group was withdrawn due to
ﬂu-like symptoms which was associated with the microdialysis
procedure.Fig. 1. Plasma concentration of diclofenac as a function of time after administra-
tion given as mean7SEM, gel application (’), iontophoretic application (~).
Table 1
Pharmacokinetic variables for plasma.
Variable Least squares mean Mean ratio 95% CI
Iontophoretic
patch
Gel
Total diclofenac (ng h/ml) 8.72 0.83 10.56 7.99, 13.95
Maximal diclofenac
concentration (ng/ml)
3.41 0.36 9.36 6.85, 12.80
Median Median
difference
95% CI
Iontophoretic
patch
Gel
Time for reaching maximal
concentration (h)
3.96 3.98 0.00 1.00, 1.00Four subjects, all in the iontophoretic patch group, developed
blisters of 0.1–0.5 cm in diameter and one also developed a skin
rash at the patch site.4. Discussion
In the present study, it was not possible to detect a meaningful
diclofenac concentration in the underlying tissues after one patch
application. This was the case for both iontophoresis and passive
delivery. The iontophoretic patch did show a facilitated transport
of diclofenac over the skin. With both application methods
diclofenac was seen to reach the circulation, but a standard gel
application only caused a plasma concentration at the limit of
detection, while iontophoretic application gave a comparably
higher and measurable plasma concentration.4.1. Penetration of topically applied diclofenac following one
application
Neither of the delivery methods caused detectable NSAID
diclofenac in the underlying subcutaneous and muscle tissue
when assessed by ultrasound-guided microdialysis, where the
measurements are guaranteed to be in the actual tissue and not
next to capillaries or a blood vessel. The iontophoretic patch was
more efﬁcient in getting diclofenac into systemic circulation, but
only in a concentration of maximum 3.4 ng/ml, while the gel
application only achieved a plasma concentration of diclofenac
around or below the sensitivity level. Comparing this to an earlier
study by Tegeder with ibuprofen [27], and taking the difference in
molecular weight into account, the topical application via ionto-
phoretic patch in the present study gave a diclofenac concentra-
tion in plasma which was 4.8% of the similar transport of
ibuprofen found by Tegeder. Since diclofenac in subcutaneous
and muscle tissue could not be detected, we conclude that
topical application of diclofenac via gel or via iontophoretic patch
did not lead to a signiﬁcant and meaningful NSAID concentration
into the tissue. A larger area of application and use of a higher
diclofenac concentration may have given some effect, as seen
by Mueller by measuring pain on Visual Analogue Scale (VAS)
[24], but even here, the topical application of diclofenac may
be said to have a small effect judging from their data. Our results
are conﬁrmed by Kienzler et al. [16] who with the same dose
of topical diclofenac on a larger (3–4 times) area obtained a
maximal plasma concentration of 15 ng/ml. The difference in
penetration through the skin layers of ibuprofen [6], which
structurally is a one-ring molecule, and diclofenac which consists
of two aromatic rings, may therefore to some extent be ex-
plained by difference in structure and size between these two
NSAIDs.
Earlier studies have shown great variability in tissue concen-
tration when looking at penetration of diclofenac applied as a gel.
These differences were explained by differences in an individual’s
skin properties [23,2]. This was further supported by a study
measuring reliability of topical application of ketoprofen [28],
where topical application did not produce a predictable concen-
tration of NSAID in the subcutaneous and muscle tissue, while
intramuscular injection showed a high reliability. This may
explain the variation in effect of topical application of NSAIDs
[28,8,18,29,19,24]. In most of these studies, the outcome measure
was furthermore improvement in pain in musculoskeletal or
experimental pain conditions. It is therefore not possible to relate
these effect data directly to our ﬁndings, since we were looking at
the actual concentration of the NSAID in the tissues to assess
actual drug penetration.
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methods
The amount of topical diclofenac found to be transported over
the skin with the iontophoretic patch application appears in
practice in systemic circulation, but probably not in a concentra-
tion that would cause any adverse effects (gastro-intestinal,
cardio-vascular). Iontophoretic application may provide an alter-
native to systemic administration, since we found average max-
imal concentrations of 3.4 ng/ml. Compared to Kienzler et al.’s
[16] 500–800 ng/ml with oral administration. Iontophoretic
administration, although safe, may though not reach effective
diclofenac concentrations.
4.3. Safety
A total of 25% of the participants reported blisters or skin
reaction at the iontophoretic patch site. Similar skin problems in
connection with iontophoretic drug delivery have been reported
earlier [15,14,17], and with the very high percentage found in our
study, this must be considered a substantial problem. The subject
withdrawing due to ﬂu-like symptoms showed symptoms which
have not been recorded in previous studies applying iontophore-
tic techniques.5. Conclusion
Topical application of diclofenac at the maximum recommended
single dose over an area of 13 cm2, by iontophoretic patch or by gel,
does not achieve a sufﬁcient concentration of the NSAID in the
underlying tissues when assessed with microdialysis.
The gel application is harmless if there is no skin allergy to the
product, while use of iontophoretic patch caused skin blisters in
25% of the subjects.Acknowledgements
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